Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS 102 and Ramucirumab in Advanced Gastric or GEJ Adenocarcinoma
NCT03686488Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Moffitt Cancer Center. Primary endpoint: Overall Survival at 6 months. Started Dec 2018; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03686488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686488.